EMAIL THIS PAGE TO A FRIEND

Journal of pharmaceutical sciences

Simulation of drug distribution in the vitreous body after local drug application into intact vitreous body and in progress of posterior vitreous detachment.


PMID 24311438

Abstract

Intravitreal injections and drug-loaded implants are current approaches to treat diseases of the posterior eye. To investigate the release of active agents and their distribution in the vitreous body, a new test system was developed that enables a realistic simulation of eye motions. It is called the eye movement system (EyeMoS). In combination with a previously developed model containing a polyacrylamide gel as a substitute for the vitreous body, this new system enables the characterization of the influence of eye motions on drug distribution within the vitreous body. In the presented work, the distribution of fluorescence-tagged model drugs of different molecular weight within the simulated vitreous was examined under movement with the EyeMoS and without movement. By replacing a part of the gel in the simulated vitreous body with buffer, the influence of the progress of posterior vitreous detachment (PVD) on the distribution of these model substances was also studied. The results indicate that convective forces may be of predominate influence on initial drug distribution. The impact of these forces on drug transport increases with simulated progression of PVD. Using the EyeMoS, the investigation of release and distribution from intravitreal drug delivery systems becomes feasible under biorelevant conditions.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A8542 Anti-Human IgG (Fab specific)−Alkaline Phosphatase antibody produced in goat, affinity isolated antibody, buffered aqueous solution
F5512 Anti-Human IgG (Fab specific)−FITC antibody produced in goat, affinity isolated antibody, buffered aqueous solution
A0293
Anti-Human IgG (Fab specific)−Peroxidase antibody produced in goat, affinity isolated antibody
SAB3701274
Anti-Human IgG (Fc specific), F(ab′)2 fragment, highly cross adsorbed antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3701267 Anti-Human IgG (Fc specific), F(ab′)2 fragment, highly cross adsorbed-Alkaline Phosphatase antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3701268
Anti-Human IgG (Fc specific), F(ab′)2 fragment, highly cross adsorbed-Biotin antibody produced in goat, affinity isolated antibody, lyophilized powder
SAB3701269
Anti-Human IgG (Fc specific), F(ab′)2 fragment, highly cross adsorbed-Fluorescein antibody produced in goat, affinity isolated antibody, lyophilized powder
SAB3701270 Anti-Human IgG (Fc specific), F(ab′)2 fragment, highly cross adsorbed-Peroxidase antibody produced in goat, affinity isolated antibody, lyophilized powder
SAB3701272 Anti-Human IgG (Fc specific), F(ab′)2 fragment, highly cross adsorbed-Rhodamine antibody produced in goat, affinity isolated antibody, lyophilized powder
SAB3701284 Anti-Human IgG (Fc specific), highly cross adsorbed antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3701277 Anti-Human IgG (Fc specific), highly cross adsorbed-Alkaline Phosphatase antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3701279 Anti-Human IgG (Fc specific), highly cross adsorbed-Biotin antibody produced in goat, affinity isolated antibody, lyophilized powder
SAB3701281 Anti-Human IgG (Fc specific), highly cross adsorbed-Fluorescein antibody produced in goat, affinity isolated antibody, lyophilized powder
SAB3701283 Anti-Human IgG (Fc specific), highly cross adsorbed-Peroxidase antibody produced in goat, affinity isolated antibody, lyophilized powder
SAB3701286 Anti-Human IgG (Fc specific), highly cross adsorbed-Rhodamine antibody produced in goat, affinity isolated antibody, lyophilized powder
A9544 Anti-Human IgG (Fc specific)−Alkaline Phosphatase antibody produced in goat, affinity isolated antibody, buffered aqueous solution
C2571
Anti-Human IgG (Fc specific)-Cy3 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
F9512
Anti-Human IgG (Fc specific)−FITC antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3701289 Anti-Human IgG (γ-chain specific), F(ab′)2 fragment antibody produced in goat, affinity isolated antibody, buffered aqueous solution
I9885 Anti-Human IgG (γ-chain specific), F(ab′)2 fragment antibody produced in goat, affinity isolated antibody, lyophilized powder
A3312
Anti-Human IgG (γ-chain specific), F(ab′)2 fragment−Alkaline Phosphatase antibody produced in goat, affinity isolated antibody, buffered aqueous glycerol solution
A5403 Anti-Human IgG (γ-chain specific), F(ab′)2 fragment−Alkaline Phosphatase antibody produced in goat, affinity isolated antibody, buffered aqueous solution
F1641 Anti-Human IgG (γ-chain specific), F(ab′)2 fragment–FITC antibody produced in goat, affinity isolated antibody, buffered aqueous solution
A2290 Anti-Human IgG (γ-chain specific), F(ab′)2 fragment−Peroxidase antibody produced in goat, affinity isolated antibody, buffered aqueous solution
A3187 Anti-Human IgG (γ-chain specific)−Alkaline Phosphatase antibody produced in goat, affinity isolated antibody, buffered aqueous glycerol solution
A3150 Anti-Human IgG (γ-chain specific)−Alkaline Phosphatase antibody produced in goat, affinity isolated antibody, buffered aqueous glycerol solution
B1140 Anti-Human IgG (γ-chain specific)-Biotin antibody produced in goat, affinity isolated antibody, buffered aqueous solution
F0132 Anti-Human IgG (γ-chain specific)−FITC antibody produced in goat, affinity isolated antibody, buffered aqueous solution
F6380 Anti-Human IgG (γ-chain specific)−FITC antibody produced in goat, IgG fraction of antiserum, buffered aqueous solution
G0786 Anti-Human IgG (γ-chain specific)−Gold antibody produced in goat, affinity isolated antibody, aqueous glycerol suspension, 5 nm (colloidal gold)